
The Evidence Based Rheumatology Podcast
A podcast for physicians about evidence based medicine in rheumatology. Each week we'll critique and apply a paper in the medical literature.
Latest Episodes
E139: HCQ + LEF in Sjögren’s Disease (RepurpSS-II)
Fun study this week on a disease I haven't discussed in quite some time. Leflunomide plus hydroxychloroquine beat placebo on ESSDAI in RepurpSS-II, a small Lancet Rheumatology trial in systemically active Sjögren’s disease. But pain, fatigue, and dryness didn’t budge. I break down ESSDAI vs ESSPRI vs STAR vs CRESS, the salivary flow cutoff to memorize, and who I’d actually treat with this combination. RepurpSS-II, Lancet Rheumatology 2026 RepurpSS-I, Lancet Rheumatology 2020
E138: Dapirolizumab for SLE (PHOENYCS-GO)
A new therapy for SLE! This one is a CD40-CD40L blocker, which has some nice new-things to inhibit. The study itself was a qualified success and the podcast got a bit more rant-y than it should have been, but hopefully you get a kick out of it. Paper: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00691-4/fulltext
E137: Obexelimab in IgG4-RD (INDIGO)
Another day, another B cell drug. This one adds an interesting option for IgG4-RD, offering a "maybe less efficacious maybe less toxic" pathway. I could see folks being excited for this, especially in a disease where non-scary-manifestations are relatively common. Also, check out boardsbank.com! Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2601337
E136: Secukinumab in PMR (REPLENISH)
Big trial this week in the NEJM investigating the IL17 inhibitor secukinumab in PMR. Well worth a read, I would bet on FDA approval in the near future. Some interesting tidbits and of course a weird safety thing we now have to grapple with. Be sure to go to boardsbank.com! Free rheumatology board review, >1000 questions! Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2602567
E135: IL17 and a GLP1?
Really interesting study this week comparing the IL17 inhibitor ixekizumab WITH the GLP1 inhibitor tirzepatide to ixekizumab alone. Raises some interesting questions about what worked here and whether or not it matters how it worked. Paper: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.70134 Newsletter: http://autoimmunedevreport.com/
E134: Brepocitinib in Dermatomyositis (VALOR)
Great trial this week looking at brepocitinib in dermatomyositis. Looks like a winner, expect it will be approved. Where it fits in our approach to IIM is an open question, but nice to have another option. Study: https://www.nejm.org/doi/10.1056/NEJMoa2503531 JC Companion: https://autoimmunedevreport.substack.com/
E133: Obinutuzumab for SLE (ALLEGORY)
Good RCT this week, investigating the CD20 B cell inhibitor obinutuzumab for SLE. Sign up for my newsletter if you would like to have a read-along companion piece! Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2516150 Landing Page: https://ebrheum.com/ Substack: https://autoimmunedevreport.substack.com/
E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE)
Quick podcast this week about a nifty head to head study that I had previously missed. Worth reading if - like me - you're still trying to figure out how the heck to manage osteoporosis. Paper: https://pubmed.ncbi.nlm.nih.gov/28755782/
E131: A Sham-Controlled Sham of a Trial: RESET-RA
Today I cover the recent publication of the RESET-RA study, which evaluated vagal nerve stimulation to treat rheumatoid arthritis. Have a listen in full, but let me be clear upfront: I do not think this works and will not be referring any patients to receive it. This will forever be my pivotal example of the effect of unblinding, but would love to hear if you think different! Paper: https://www.nature.com/articles/s41591-025-04114-7 Supplement (see S4): https://www.nature.com/articles/s41591-025…
E130: Telitacicept for SLE
Surprisingly (unbelievably?) impressive RCT evaluating the Blys/APRIL inhibitor "telitacicept" for patients with SLE (mixed SLE and SLE-LN). Very curious to see where the FDA goes with this one. Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2414719
E129: Long Term Routine Laboratory Monitoring in RA
Ever wonder how often you really need to check "monitoring" labs? If so then this is the podcast for you! Bryant England mentioned this during his excellent Year in Review session at ACR Convergence 2025. I've been meaning to cover it and finally got around to doing so. Have a listen and share with friends! Paper: https://pubmed.ncbi.nlm.nih.gov/40854212/
E128: Nerandomilast for Autoimmune ILD (FIBRONEER-ILD)
Covering a very interesting study this week, which investiaged the PDE4B inhibitor nerandomilast for patients with progressive pulmonary fibrosis (specifically including 325 patients with autoimmune ILD). Would have been yet another ho hum trial if not for the big reveal... have a listen to find out! Article: https://www.nejm.org/doi/full/10.1056/NEJMoa2503643
E127: TNFs and All That CHF
Another episode looking into safety this week! Tackling that pesky issue of TNFs and CHF. Be sure to subscribe to my newsletter and check out the papers below! Newsletter: https://sprw.io/stt-ee87b4 ATTACH: https://pubmed.ncbi.nlm.nih.gov/12796126/ RENEWAL: https://www.ahajournals.org/doi/10.1161/01.cir.0000124490.27666.b2 Observational Studies: https://pubmed.ncbi.nlm.nih.gov/23155221/
E126: Risk Signals, JAKs, and SELECTIVE-ity
Covering an interesting but ultimately disappointing post hoc study of multiple upadacitinib trials in RA. Initially some hope for clarity in the "Do JAKs cause all the badness?" questions, but ultimately landing me about where I have been since ORAL-SURVEILLANCE was published Paper: https://www.sciencedirect.com/science/article/pii/S0003496724423091
E125: Adrenal Insufficiency after Stopping Prednisone
Interesting read this week - I cover a nifty little paper that presented data about adrenal insufficiency after stopping prednisolone, published in JAMA Open in March 2025. Open Access Journal Here: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831668
e124: MTX vs Pred for Pulmonary Sarcoidosis: PREDMETH Study
Interesting NEJM trial this week comparing methotrexate to prednisone for pulmonary sarcoidosis. Paper available here: https://www.nejm.org/doi/full/10.1056/NEJMoa2501443
E123: Upadacitinib for Giant Cell Arteritis: SELECT-GCA
Podcast this week about the recently published SELECT-GCA study, which evaluated the use of the janus kinase inhibitor upadacitinib (Rinvoq) for patients with new and relapsing GCA. Successful trial and an interesting topic. Paper itself here: https://www.nejm.org/doi/full/10.1056/NEJMoa2413449
E122: Guidelines for Maybe Diagnosing HLH
This week I cover another of my newsletters, though I mostly use it as a skeleton to riff on a common (and challenging) issue for rheumatology consultants; diagnosing HLH. Check out the guidelines themselves here and have a listen to the podcast! https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00273-4/fulltext
E121: Obinutuzumab in SLE-LN
Another day, another b cell podcast. Seems to be all the rage! This week I discuss the recently published NEJM trial of the anti CD20 agent obinutuzumab in lupus nephritis. Worth a read and listen, paper can be found here: https://www.nejm.org/doi/full/10.1056/NEJMoa2410965
E120: Real Life Use of PEXIVAS-Low
What do you do when observational data and RCTs conflict? This week I'm covering the "real world PEXIVAS" study that was done by the French Vasculitis Study Group. Great read, interesting issues, have a listen and be sure to share with friends!





